Entasis Therapeutics

Entasis Therapeutics

  • Founded: 2015
  • Location: Waltham, MA
  • Employee range: 50 - 200
  • Clinical stage: NDA
  • Therapy area: Multidrug resistant Acinetobacter infections (Partner: ZaiLab)
  • Drug types: INF
  • Lead product: Sulbactam-Durlobactam
  • Product link: https://www.entasistx.com/pipeline
  • Funding: $20M stock May 2021; $25M stock Aug 2020; $35M stock Apr 2020; $10M Jan 2019; $75M IPO Sep 2018; $32M B-2 Sep 2017; $50M B Apr 2016



job board

Short description:

Small molecule anti-infectives

Drug notes:

Zoliflodacin (partners: GARDP, NIH) Clin3 gonorrhea; ETX0282CPDP (partner: CARB-X) Clin1 complicated UTIs ; ETX0462 (partner: CARB-X) Clin0 Gram-negative infections

Long description:

Entasis Therapeutics is focused on finding ways to overcome multi-drug resistant bacteria. Due to their rapid growth and short lifespan, bacteria have evolved multiple mechanisms to overcome current antibiotics. To find effective novel molecules that overcome these resistance mechanisms Entasis is using a targeted approach since different bacteria have unique mechanisms of action. For example, Entasis recently completed their program against multidrug resistant Acinetobacter infections with their drug Sulbactam-Durlobactam, a combination of beta-lactam antibiotic and a beta-lactamase inhibitor. Entasis’ pipeline also includes Zoliflodacin, a novel oral antibiotic in Phase 3 clinical trials against uncomplicated gonorrhea.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com